BR112016002317A8 - Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos - Google Patents

Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos

Info

Publication number
BR112016002317A8
BR112016002317A8 BR112016002317A BR112016002317A BR112016002317A8 BR 112016002317 A8 BR112016002317 A8 BR 112016002317A8 BR 112016002317 A BR112016002317 A BR 112016002317A BR 112016002317 A BR112016002317 A BR 112016002317A BR 112016002317 A8 BR112016002317 A8 BR 112016002317A8
Authority
BR
Brazil
Prior art keywords
benralizumab
antigen
binding fragment
asthmatics
expiratory volume
Prior art date
Application number
BR112016002317A
Other languages
English (en)
Other versions
BR112016002317A2 (pt
Inventor
Ward Christine
Roskos Lorin
Wang Bing
Raible Donald
Original Assignee
Medimmune Llc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Astrazeneca Ab filed Critical Medimmune Llc
Publication of BR112016002317A2 publication Critical patent/BR112016002317A2/pt
Publication of BR112016002317A8 publication Critical patent/BR112016002317A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)

Abstract

USO DE BENRALIZUMAB OU DE UM SEU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO PARA AUMENTAR O VOLUME EXPIRATÓRIO FORÇADO EM ASMÁTICOS E BENRALIZUMAB OU DE UM SEU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO PARA USO PARA AUMENTAR O VOLUME EXPIRATÓRIO FORÇADO EM ASMÁTICOS. A invenção refere-se a métodos para aumento do volume expiratório forçado em um segundo (FEV1) em um paciente com asma, compreendendo a administração ao paciente de uma quantidade eficaz de benralizumab ou de um seu fragmento de ligação ao antígeno.
BR112016002317A 2013-08-12 2014-08-07 Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos BR112016002317A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (2)

Publication Number Publication Date
BR112016002317A2 BR112016002317A2 (pt) 2017-12-12
BR112016002317A8 true BR112016002317A8 (pt) 2018-06-12

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002317A BR112016002317A8 (pt) 2013-08-12 2014-08-07 Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos

Country Status (25)

Country Link
US (1) US9441046B2 (pt)
EP (3) EP3520811B1 (pt)
JP (3) JP6746496B2 (pt)
KR (1) KR102337599B1 (pt)
CN (2) CN111588849A (pt)
AU (2) AU2014306959B2 (pt)
BR (1) BR112016002317A8 (pt)
CA (1) CA2917603C (pt)
CY (2) CY1122033T1 (pt)
DK (2) DK3033104T3 (pt)
ES (2) ES2733602T3 (pt)
HK (2) HK1222559A1 (pt)
HR (2) HRP20190920T1 (pt)
HU (2) HUE043497T2 (pt)
LT (2) LT3520811T (pt)
ME (1) ME03403B (pt)
MX (2) MX2016001384A (pt)
PL (2) PL3520811T3 (pt)
PT (2) PT3033104T (pt)
RS (2) RS61565B1 (pt)
RU (1) RU2703568C2 (pt)
SG (1) SG11201600483QA (pt)
SI (2) SI3033104T1 (pt)
TR (1) TR201907907T4 (pt)
WO (1) WO2015023507A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3988114A1 (en) * 2013-08-12 2022-04-27 Astrazeneca AB Methods for improving asthma symptoms using benralizumab
HUE042607T2 (hu) * 2013-08-12 2019-07-29 Astrazeneca Ab Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával
BR112016008082A2 (pt) * 2013-10-15 2017-10-17 Medimmune Llc métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab
KR102238065B1 (ko) * 2013-10-24 2021-04-07 아스트라제네카 아베 안정한 수성 항체 제제
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283926T1 (de) 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
JPWO2005035583A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｉｌ−５受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
MX2009012341A (es) 2007-05-14 2010-02-17 Medimmune Llc Metodos para reducir niveles de eosinofilos.
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
AR084342A1 (es) * 2010-12-16 2013-05-08 Genentech Inc Diagnostico y tratamientos relacionados con la inhibicion de th2
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
JP2014533246A (ja) * 2011-11-01 2014-12-11 メディミューン，エルエルシー 喘息の急性増悪の頻度および重症度を低下させる方法
HUE042607T2 (hu) * 2013-08-12 2019-07-29 Astrazeneca Ab Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával
EP3988114A1 (en) * 2013-08-12 2022-04-27 Astrazeneca AB Methods for improving asthma symptoms using benralizumab

Also Published As

Publication number Publication date
US9441046B2 (en) 2016-09-13
DK3520811T3 (da) 2021-03-22
EP3520811B1 (en) 2020-12-30
CY1124399T1 (el) 2022-07-22
AU2014306959B2 (en) 2019-11-21
HUE043497T2 (hu) 2019-08-28
US20150044203A1 (en) 2015-02-12
CA2917603C (en) 2023-05-16
HRP20190920T1 (hr) 2019-07-12
CN105451769A (zh) 2016-03-30
RS58711B1 (sr) 2019-06-28
ME03403B (me) 2020-01-20
WO2015023507A3 (en) 2015-04-09
TR201907907T4 (tr) 2019-06-21
LT3520811T (lt) 2021-03-25
HK1222559A1 (zh) 2017-07-07
HK1225300A1 (zh) 2017-09-08
EP3033104A4 (en) 2017-03-22
EP3875487A1 (en) 2021-09-08
ES2733602T3 (es) 2019-12-02
PL3520811T3 (pl) 2021-08-02
AU2014306959A1 (en) 2016-02-04
RU2016108809A3 (pt) 2018-06-18
SI3033104T1 (sl) 2019-06-28
JP2016527325A (ja) 2016-09-08
PL3033104T3 (pl) 2019-09-30
MX2016001384A (es) 2016-08-03
PT3520811T (pt) 2021-03-15
BR112016002317A2 (pt) 2017-12-12
CN111588849A (zh) 2020-08-28
CY1122033T1 (el) 2020-10-14
RU2016108809A (ru) 2017-09-18
DK3033104T3 (da) 2019-06-17
EP3033104A2 (en) 2016-06-22
HUE053627T2 (hu) 2021-07-28
WO2015023507A2 (en) 2015-02-19
HRP20210406T1 (hr) 2021-04-30
AU2020201277A1 (en) 2020-03-12
PT3033104T (pt) 2019-06-27
ES2866426T3 (es) 2021-10-19
LT3033104T (lt) 2019-06-25
CA2917603A1 (en) 2015-02-19
EP3520811A1 (en) 2019-08-07
MX2021003826A (es) 2021-05-27
SI3520811T1 (sl) 2021-04-30
JP2020125304A (ja) 2020-08-20
SG11201600483QA (en) 2016-02-26
WO2015023507A8 (en) 2015-09-24
RU2703568C2 (ru) 2019-10-21
RS61565B1 (sr) 2021-04-29
KR20160043049A (ko) 2016-04-20
KR102337599B1 (ko) 2021-12-10
JP2022120010A (ja) 2022-08-17
EP3033104B1 (en) 2019-04-03
JP6746496B2 (ja) 2020-08-26

Similar Documents

Publication Publication Date Title
BR112016002317A8 (pt) Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
BR112016012968A2 (pt) Métodos e composições para o tratamento de condições associadas com o envelhecimento
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112013022391A2 (pt) composições, métodos de tratamento e diagnóstico para o tratamento de esteatose hepática apenas ou em combinação com uma infecção pelo vírus da hepatite c e uso dessas composições
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112016004324A2 (pt) anticorpos
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
WO2012121977A3 (en) Dodecafluoropentane emulsion as a stroke and ischemia therapy
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.